Health Care • Biotechnology: Pharmaceutical Preparations
$0.86 ▼ +0.00
(-0.13%)
MKT CAP: $53.3M • VOL: 169.5K
52W L $1 52W H $2
ROARABLE / RQD
D • 44/100
PIOTROSKI
2 / 9
PLRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $1.6M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$156.4M | -$228.4M | -$184.1M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | $149.3M | $210.3M | $161.3M |
| EBITDA (Normalized) | -$156.1M | -$225.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$128.3M | -$155.5M | -$116.4M |
| Capital Expenditures (CapEx) | $374.0K | $3.8M | — |
| Free Cash Flow (FCF) | -$128.7M | -$159.4M | -$116.4M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $45.4M | $71.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $181.2M | $304.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PLRX.